Wave Life Sciences Ltd.
NASDAQ:WVEBiotechnology
+$0.10 today
- Market cap
- $546.32M
- Beta
- -1.33
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$0.92
Volume 2.21M
Average 4.86M
WVE Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Wave Life Sciences Ltd.NASDAQ: WVE
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $47.44M rose 16.8% year over year, ahead of the +13.6% change in trailing-twelve-month research & development. Sequentially, it fell 10.2% from the prior quarter. Over 3 fiscal years it compounded at +16.4% a year.
Context
- Research & development amounted to 427.8% of revenue in FY2025, up 280.3 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +16.8% holds above the trailing-twelve-month pace of +13.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 182.78M USD
- Year-over-year change
- +14.5%
- 4-year CAGR
- +10.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 182.78M | +14.5% |
| FY2024 | 2024-12-31 | 159.68M | +22.8% |
| FY2023 | 2023-12-31 | 130.01M | +12.2% |
| FY2022 | 2022-12-31 | 115.86M | -4.9% |
| FY2021 | 2021-12-31 | 121.88M | — |
Research & Development vs competitors
How WVE compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +13.6% is the 4th highest of 10, against a peer median of +4.7%.
- Research & development amounts to 264.1% of revenue for WVE, versus a peer median of 216.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.51B USD | +30.1% | +14.5% | 31.4% | |
| LTM Sep 2026 | $923.16M USD | +4.7% | +3.2% | 96.2% | |
| LTM Mar 2026 | $902.58M USD | -34.5% | +20.2% | 41.3% | |
| LTM Sep 2026 | $739.14M USD | +21.7% | +29.3% | 164.0% | |
| LTM Mar 2026 | $361.17M USD | -21.5% | -2.5% | 546.5% | |
| LTM Mar 2026 | $189.6M USD | +13.6% | +16.4% | 264.1% | |
| LTM Mar 2026 | $144.07M USD | +45.7% | +21.0% | 449.1% | |
| LTM Mar 2026 | $98.25M USD | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | $61.84M USD | — | +24.0% | 6710.8% | |
| LTM Mar 2026 | €44.34M EUR | +12.6% | -7.1% | 329.9% | |
| LTM Mar 2026 | $19.2M USD | +1.2% | +17.6% | — | |
| Peer median (excluding WVE) | — | +4.7% | +16.0% | 216.6% | |
Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 40.96M | 3.65M | 113.31M | 108.3M | 42.73M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 8.85M |
| Gross Profit | 40.96M | 3.65M | 113.31M | 108.3M | 33.88M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 79.3% |
| Research & Development | 121.88M | 115.86M | 130.01M | 159.68M | 182.78M |
| Selling, General & Admin | 46.11M | 50.51M | 51.29M | 59.02M | 75.33M |
| Operating Expenses | 167.98M | 166.37M | 181.3M | 218.71M | 249.26M |
| Depreciation & Amortization | 9.84M | 10.11M | 9.21M | 8.66M | 8.85M |
| EBITDA | (112.61M) | (151.03M) | (48.98M) | (88.35M) | (195.53M) |
| EBITDA Margin | -274.9% | -4138.9% | -43.2% | -81.6% | -457.6% |
| Operating Income | (127.02M) | (162.72M) | (68M) | (110.4M) | (215.38M) |
| Operating Margin | -310.1% | -4459.3% | -60.0% | -101.9% | -504.1% |
| Interest Income | 30K | 0 | 0 | 0 | 10.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.57M | 1.58M | 9.81M | 13.4M | 11.01M |
| Income Before Tax | (122.45M) | (161.14M) | (58.19M) | (97.01M) | (204.38M) |
| Pre-Tax Margin | -298.9% | -4416.1% | -51.4% | -89.6% | -478.3% |
| Income Tax Expense | (204K) | 681K | (677K) | 0 | 0 |
| Net Income | (122.25M) | (161.82M) | (57.51M) | (97.01M) | (204.38M) |
| Net Margin | -298.4% | -4434.7% | -50.8% | -89.6% | -478.3% |
| EPS (Basic) | (2.36) | (2.05) | (0.54) | (0.70) | (1.21) |
| EPS (Diluted) | (2.36) | (2.05) | (0.54) | (0.70) | (1.21) |
| Weighted Avg Shares | 51.83M | 78.86M | 106.1M | 138.28M | 168.65M |
| Weighted Avg Shares (Diluted) | 51.83M | 78.86M | 106.1M | 138.28M | 168.65M |
Wave Life Sciences Ltd.
NASDAQ:WVE
Intrinsic Alpha fair value
Locked
Current Price
$2.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.